向榮生醫科技股份有限公司 Approved
最後更新時間 2025/07/18 , 07:14 AM
最後更新時間 2025/07/18 , 07:14 AM
負責人
Cai,Yi-Wen
統一編號
50753953
成立日期
2018/03/28
資本額
NT$1,000,000,000
實收資本額
NT$606,790,000
股票代號
6794
電話
02-27922699
地址
5F, No. 13-20, Sec. 6, Mincyuan E. Rd., Neihu Dist., Taipei City, 114, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Cai,Yi-Wen Chairman 4.02%
Zhang,Jia-Fang Director 0.00%
Xie,Xiu-Mei Director 16.31% Jing Chi Biomed Co., Ltd.
SHIN YANG STEEL CO., LTD. Director 13.18%
Ling,Mei-Hua Director 4.43%
Qiu,Yu-Cheng Director 0.00%
Shi,Yao-Tang Independent Director 0.00%
Chen,Cheng-Ren Independent Director 0.00%
Lin,Su-Lan Independent Director 0.00%
營業項目
  • Wholesale of Cosmetics(457299)
  • Retail Sale of Cosmetics in Specialized Stores(475299)
  • Other Technical Testing and Analysis(712999)
  • Manufacture of Cosmetics(193299)
  • 公司歷程
  • Change Capital to 1,000,000,000
    2023/08/04
  • Change Person in Charge to Cai,Yi-Wen
    2020/11/10
  • Change Capital to 600,000,000
    2019/05/20
  • Change Capital to 360,000,000
    2018/08/17
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2025 2024 2023
    Operating income 9,846 31,881 24,589
    Operating cost 3,316 11,311 6,692
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 6,530 20,570 17,897
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 6,530 20,570 17,897
    Operating expenses 37,690 123,490 114,177
    Other gain (loss), net - - -
    Operating profit (loss) -31,160 -102,920 -96,280
    Non-operating income and expenses 2,819 9,848 12,172
    Net profit (loss) before tax -28,341 -93,072 -84,108
    Income tax expense (benefits) - - -
    Net profit (loss) of ongoing business for the current period -28,341 -93,072 -84,108
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -28,341 -93,072 -84,108
    Other comprehensive profit (loss), net - - -
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -28,341 -93,072 -84,108
    Net profit (loss) attributable to owners of parent company - - -
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests - - -
    Comprehensive profit (loss) attributable to owners of parent company - - -
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests - - -
    Basic earnings per share (yuan) 0 -1 -1
    項目 2025 2024 2023
    Net cash inflow (outflow) from operating activities -27,482 - -
    Net cash inflows (outflows) from investing activities 54,065 - -
    Net cash inflow (outflow) from financing activities 120,953 - -
    Effect of Exchange Rate Changes on Cash and Cash Equivalents - - -
    Increase (decrease) in cash and cash equivalents in the current period 147,536 - -
    Beginning balance of cash and cash equivalents 9,571 - -
    Ending balance of cash and cash equivalents 157,107 - -
    項目 2025 2024 2023
    Current asset 681,794 592,350 506,796
    Non-current asset 182,072 185,539 179,133
    Total asset 863,866 777,889 685,929
    Current liability 19,558 27,130 16,901
    Non-current liability 64,622 66,151 72,586
    Total liability 84,180 93,281 89,487
    share capital 606,108 584,108 556,845
    Equity - secruity token - - -
    capital reserve 807,284 705,865 551,890
    retained earning -633,706 -605,365 -512,293
    Other equity - - -
    Treasury stock - - -
    Total equity attributable to owners of parent company - - -
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests - - -
    Total Equity 779,686 684,608 596,442
    Share capital awaiting retirement (unit: share) 0 0 0
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 12 11 10
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • 效膝膝
  • Exofectin
  • EXCYTIN Biomed
  • EXCYTIN
  • 向榮生醫科技股份有限公司標章
  • UnicoCell
  • UnicoSkin設計圖
  • 優易保
  • ELIXOME
  • UnicoVial
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
    勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。